<DOC>
	<DOCNO>NCT00497666</DOCNO>
	<brief_summary>Recent data show Rosiglitazone treatment reduce proteinuria diabetic patient . However , currently trial examine effect Rosiglitazone kidney disease progression , , double serum creatinine time onset end-stage renal disease , patient diabetic nephropathy . We decide study retrospectively possible association rosiglitazone use clinical course diabetic nephropathy , include rate deterioration renal function , appearance progression microalbuminuria/proteinuria , survival acceptance renal replacement therapy .</brief_summary>
	<brief_title>Association Between Rosiglitazone Use Clinical Course Diabetic Nephropathy : Population-Based Study</brief_title>
	<detailed_description>Background Type 2 diabetes mellitus public health concern , projection future effect alarming . According World Health Organization , diabetes affect 170 million people worldwide , number rise 370 million 2030 [ 1 ] . About one third affect eventually progressive deterioration renal function [ 2 , 3 ] . The first clinical sign renal dysfunction patient diabetes generally microalbuminuria ( sign endothelial dysfunction necessarily confine kidney ) [ 4 ] , develop 2 5 percent patient per year [ 5,6 ] . In type 2 diabetes , unlike type 1 diabetes [ 7 ] , microalbuminuria seldom reversible [ 8 ] , , instead , progress overt proteinuria 20 40 percent patients. [ 9,10 ] . In 10 50 percent patient proteinuria , chronic kidney disease develop ultimately require dialysis transplantation [ 11,12,13 ] . Forty 50 percent patient type 2 diabetes microalbuminuria eventually die cardiovascular disease [ 14,15 ] ; three time high rate death cardiac cause among patient diabetes evidence renal disease [ 6 ] . In patient diabetes renal disease , lower blood pressure level urinary albumin effective reduce risk end-stage renal disease well myocardial infarction , heart failure , stroke [ 16 ] . Angiotensin-converting–enzyme ( ACE ) inhibitor angiotensin II antagonist appear effective renoprotective antihypertensive agent [ 11 , 12 , 17-21 ] . Treatment ACE inhibitor enalapril period six year decrease incidence microalbuminuria patient type 2 diabetes normotensive obese [ 22 ] . Preventing ( delay ) development microalbuminuria key treatment goal renoprotection [ 23 ] , possibly , cardioprotection [ 4 ] . Recent clinical trial suggest inhibition renin–angiotensin system may actually prevent nephropathy . The post hoc analyse reduction hypertension Heart Outcomes Prevention Evaluation study [ 18 ] Losartan Intervention Endpoint study [ 24 ] find low incidence overt nephropathy subject type 2 diabetes receive therapy inhibit renin–angiotensin system control . Recent BENEDICT study indicate treatment trandolapril without verapamil significantly reduce incidence microalbuminuria patient type 2 diabetes normal urinary albumin excretion , compare placebo [ 25 ] . Trandolapril alone also appear decrease incidence microalbuminuria , whereas verapamil effect . Thiseffect trandolapril plus verapamil trandolapril alone prevent microalbuminuria exceed expectation base change blood pressure alone . Unfortunately , even appropriate use available therapy , diabetic nephropathy still remain leading cause ESRD [ 2 ] . More effective strategy need order retard progression diabetic nephropathy reduce cardiovascular mortality diabetic population . Thiazolidinediones ( TZDs ) represent class compound currently use treatment type 2 DM exert hypoglycemic property reduction IR [ 26 ] . These agent act stimulate certain type nuclear receptor , call peroxisome proliferator-activated receptor gamma ( PPAR ) . Such receptor abundant adipose tissue cell , also present various cell type , vascular smooth muscle cell , macrophage , vascular endothelial cell , colon epithelial cell , well renal glomerular tubular cell . Through transcriptional regulation various gene , PPAR receptor play important role adipocyte differentiation lipid carbohydrate metabolism [ 26 ] . Apart improve glycemic control patient type 2 DM , several line evidence support notion TZDs beneficial effect component metabolic syndrome , blood pressure ( BP ) lowering , triglyceride reduction , high-density lipoprotein–cholesterol elevation , redistribution body fat away central compartment , decrease C-reactive protein plasminogen activator inhibitor -1 ( PAI-1 ) level , others [ 26 ] . Additionally , several animal study demonstrate TZDs also reduce urine albumin protein excretion protect injury kidney [ 27 ] . Moreover , experimental study expose numerous action TZDs kidney could explain possible renoprotective effect [ 27-30 ] . Our recent study diabetic rat show rosiglitazone exerts anti-inflammatory renoprotective effect inhibition mesangial cell proliferation , downregulation apoptosis blunt responsiveness angiotensin-2 [ 31 ] . Human study also report significant reduction UAE among patient type 2 diabetes rosiglitazone [ 32 ] . Another human study part cardiac safety study rosiglitazone 4 mg b.i.d . compare glyburide 121 patient 52 week [ 32 ] . After 28 week treatment , group significant reduction ACR 30 % , 52 week rosiglitazone group continue demonstrate significant ACR reduction . This finding suggest duration follow-up important variable assess effect TZDs [ 32 ] . Overall , data clearly show TZD treatment reduce UAE . However , emphasize currently trial examine effect TZDs kidney disease progression , , double serum creatinine time onset end-stage renal disease , patient diabetic nephropathy [ 33 ] . Such study need order provide best evidence renoprotective effect TZDs . Based data , decide study possible association rosiglitazone use clinical course diabetic nephropathy , include rate deterioration renal function , appearance progression microalbuminuria/proteinuria , survival acceptance renal replacement therapy . Methods . Study population . The study plan retrospective cohort study use automated clinical data Central Region Clalit Health Survices 1999 2007 . Inclusion criterion : 1 . Diagnosis Diabetes Mellitus Type II ; 2 . Treatment With Oral hypoglycemics ; 3 . Availability Baseline follow clinical data Exclusion criterion : 1 . Insulin Therapy baseline ; 2 . Malignancy Patients divide 2 group : rosiglitazone-treated group non-treated rosiglitazone ( control ) group . Baseline Data ( separately two group ) . Number patient . Gender Race/etnicity Age Weight , BMI Duration DM Diabetic microangiopathy : retinopathy , neuropathy , nephropathy Medications DM Creatinine Microalbumin Proteinuria HbA1c % Hb Ca , P , PTH Albumin Hypertension : BP Cholesterol , LDL , TG Smoking : current , previous Alcohol consumption Comorbidites : HTN , CAD , CHF , PVD , Hypercholesterolemia , CVA/TIA Drugs : ACEi , ARBs , CCB , beta-blockers , statines , antiplatlate Use nephrotoxic medication : NSAIDs Follow data Duration rosiglitasone therapy/follow Use contrast medium study Every year data : Creatinine eGFR Microalbumin Proteinuria HbA1C % Start insulin therapy Events : Hospitalisation ( cause ) Death ( cause ) ESRD/Dialysis Reported CHF MI CVA Angiography PVD Amputation References 1 . World Health Organization . The Diabetes Program 2004 . ( http : //www.who.int/diabetes/en/ . ) 2 . Remuzzi G , Schieppati A , Ruggenenti P. Nephropathy patient type 2 diabetes . N Engl J Med 2002 ; 346:1145-1151 . 3 . Ruggenenti P , Remuzzi G. The diagnosis renal involvement non-insulin-dependent diabetes mellitus . Curr Opin Nephrol Hypertens 1997 ; 6:141-145 . 4 . Ritz E. Albuminuria vascular damage -- vicious twin . N Engl J Med 2003 ; 348:2349-2352 . 5 . Gall MA , Hougaard P , Borch-Johnsen K , Parving HH . Risk factor development incipient overt diabetic nephropathy patient non-insulin dependent diabetes mellitus : prospective , observational study . BMJ 1997 ; 314:783-788 . 6 . Adler AI , Stevens RJ , Manley SE , Bilous RW , Cull CA , Holman RR . Development progression nephropathy type 2 diabetes : United Kingdom Prospective Diabetes Study ( UKPDS 64 ) . Kidney Int 2003 ; 63:225-232 . 7 . Perkins BA , Ficociello LH , Silva KH , Finkelstein DM , Warram JH , Krolewski AS . Regression microalbuminuria type 1 diabetes . N Engl J Med 2003 ; 348:2285-2293 8 . Parving HH , Lehnert H , Brochner-Mortensen J , Gomis R , Andersen S , Arner P. The effect irbesartan development diabetic nephropathy patient type 2 diabetes . N Engl J Med 2001 ; 345:870-878 9 . Mogensen CE . Microalbuminuria predict clinical proteinuria early mortality maturity-onset diabetes . N Engl J Med 1984 ; 310:356-360 10 . Nelson RG , Knowler WC , Pettitt DJ , Saad MF , Charles MA , Bennett PH . Assessing risk overt nephropathy diabetic patient albumin excretion untimed urine specimen . Arch Intern Med 1991 ; 151:1761-1765 . 11 . Brenner BM , Cooper ME , de Zeeuw D , et al . Effects losartan renal cardiovascular outcome patient type 2 diabetes nephropathy . N Engl J Med 2001 ; 345:861-869 . 12 . Lewis EJ , Hunsicker LG , Clarke WR , et al . Renoprotective effect angiotensin receptor antagonist irbesartan patient nephropathy due type 2 diabetes . N Engl J Med 2001 ; 345:851-860 . 13 . Nelson RG , Newman JM , Knowler WC , et al . Incidence end-stage renal disease type 2 ( non-insulin-dependent ) diabetes mellitus Pima Indians . Diabetologia 1988 ; 31:730-736 14 . Eurich DT , Majumdar SR , Tsuyuki RT , Johnson JA . Reduced mortality associate use ACE inhibitor patient type 2 diabetes . Diabetes Care 2004 ; 27:1330-1334 . 15 . Parving HH , Mauer M , Ritz E. Diabetic nephropathy . In : Brenner BM , ed . Brenner &amp; Rector 's The kidney . 7th ed . Vol . 2 . Philadelphia : Saunders , 2004:1777-818 . 16 . Dinneen SF , Gerstein HC . The association microalbuminuria mortality non-insulin-dependent diabetes mellitus : systematic overview literature . Arch Intern Med 1997 ; 157:1413-1418 17 . Parving HH , Jacobsen P , Rossing K , Smidt UM , Hommel E , Rossing P. Benefits long-term antihypertensive treatment prognosis diabetic nephropathy . Kidney Int 1996 ; 49:1778-1782 18 . Heart Outcomes Prevention Evaluation ( HOPE ) Study Investigators . Effects ramipril cardiovascular microvascular outcome people diabetes melllitus : result HOPE study MICRO-HOPE substudy . Lancet 2000 ; 355:253-259 . [ Erratum , Lancet 2000 ; 356:860 . ] 19 . Viberti G , Mogensen CE , Groop LC , Pauls JF . Effect captopril progression clinical proteinuria patient insulin-dependent diabetes mellitus microalbuminuria . JAMA 1994 ; 271:275-279 . 20 . Ravid M , Lang R , Rachmani R , Lishner M. Long-term renoprotective effect angiotensin-converting enzyme inhibition non-insulin-dependent diabetes mellitus : 7-year follow-up study . Arch Intern Med 1996 ; 156:286-289 21 . Lewis EJ , Hunsicker LG , Bain RF , Rohde RD . The effect angiotensin-converting-enzyme inhibition diabetic nephropathy . N Engl J Med 1993 ; 329:1456-1462 . [ Erratum , N Engl J Med 1993 ; 330:152 . 22 . Ravid M , Brosh D , Levi Z , Bar-Dayan Y , Ravid D , Rachmani R. Use enalapril attenuate decline renal function normotensive , normoalbuminuric patient type 2 diabetes mellitus : randomize , control trial . Ann Intern Med 1998 ; 128:982-988 23 . UK Prospective Diabetes Study ( UKPDS ) Group . Intensive blood-glucose control sulphonylureas insulin compare conventional treatment risk complication patient type 2 diabetes ( UKPDS 33 ) . Lancet 1998 ; 352:837-853 . [ Erratum , Lancet 1999 ; 354:602 . ] 24 . Lindholm LH , Ibsen H , Dahlof B , et al . Cardiovascular morbidity mortality patient diabetes Losartan Intervention For Endpoint reduction hypertension study ( LIFE ) : randomize trial atenolol . Lancet 2002 ; 359:1004-1010 . 25 . Ruggenenti P , Fassi A , Ilieva A , et al . Preventing Microalbuminuria Type 2 Diabetes . N Engl J Med 2004 ; 351 : 1941-51 . 26 . Lebovitz HE , Banerji MA . Insulin resistance treatment thiazolidinediones . Recent Prog Horm Res 2001 ; 56 : 265–294 . 27 . Haneda M , Koya D , Kikkawa R. Cellular mechanisms development progression diabetic nephropathy : activation DAG-PKC-ERK pathway . Am J Kidney Dis 2001 ; 38 : S178–S181 28 . Asano T , Wakisaka M , Yoshinari M et al . Peroxisome proliferator-activated receptor gamma1 ( PPARgamma1 ) express rat mesangial cell PPARgamma agonist modulate differentiation . Biochim Biophys Acta 2000 ; 1497 : 148–154 29 . Xiong Z , Huang H , Li J et al . Anti-inflammatory effect PPARgamma culture human mesangial cell . Renal Failure 2004 ; 26 : 497–505 . 30 . Gumieniczek A . Effect new thiazolidinedione–pioglitazone development oxidative stress liver kidney diabetic rabbit . Life Sci 2003 ; 74 : 553–562 31 . Weissgarten J , Berman S , Efrati S , et al . Apoptosis proliferation culture mesangial cell isolate kidney rosiglitasone-treated pregnant diabetic rat . Nephrol Dial Transplant 2006 ; 21 : 1198-204 32 . Bakris G , Viberti G , Weston WM et al . Rosiglitazone reduce urinary albumin excretion type 2 diabetes . J Hum Hypertens 2003 ; 17 : 7–12 . 33 . Sarafidis P , Bakris G. Protection kidney thiazolidinediones : An assessment bench bedside . Kidney Int 2006 ; 70 : 1223-1233 .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>1 . Diagnosis Diabetes Mellitus Type II 2 . Treatment With Oral hypoglycemics 3 . Availability Baseline follow clinical data 1 . Insulin Therapy baseline 2 . Malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Diabetic nephropathy</keyword>
	<keyword>renal protection</keyword>
</DOC>